In contrast, tumor-suppressive miRNAs, such as miR-132 and miR-422a, inhibit TGF-β-induced EMT by targeting pathway components, including TGF-β1, SMAD2, and associated EMT markers. The gene discussed is SMAD2; the disease is neoplasm.